Dr. Tchekmedyian is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
265 Western Ave
South Portland, ME 04106Phone+1 207-661-0200Fax+1 207-661-0299
Education & Training
- Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2019
- Brigham and Women's HospitalResidency, Internal Medicine, 2011 - 2014
- David Geffen School of Medicine at UCLAClass of 2011
Certifications & Licensure
- ME State Medical License 2019 - 2025
- NY State Medical License 2016 - 2020
- MA State Medical License 2014 - 2017
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 298 citationsClonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for LymphomaChristopher J. Gibson, R. Coleman Lindsley, Vatche Tchekmedyian, Brenton G. Mar, Jiantao Shi
Journal of Clinical Oncology. 2017-01-09 - 131 citationsPhase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma.Vatche Tchekmedyian, Eric J. Sherman, Lara Dunn, Crystal Tran, Shrujal S. Baxi
Journal of Clinical Oncology. 2014-05-20 - 133 citationsVemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers.Lara Dunn, Eric J. Sherman, Shrujal S. Baxi, Vatche Tchekmedyian, Ravinder K. Grewal
The Journal of Clinical Endocrinology and Metabolism. 2019-05-01
Lectures
- A retrospective analysis of cisplatin dosing strategies when used with radiation on outcomes in head and neck squamous cell carcinoma of the oropharynx.2019 ASCO Annual Meeting - 6/1/2019
- A phase II trial cohort of nivolumab plus ipilimumab in patients (Pts) with recurrent/metastatic adenoid cystic carcinoma (R/M ACC).2019 ASCO Annual Meeting - 6/1/2019
- A phase II study of lenvatinib in patients with progressive, recurrent/metastatic adenoid cystic carcinoma.2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: